CVE-2026-33529Zoraxy is a general purpose HTTP reverse proxy and forwarding tool.
Updated under an hour ago ()
Does this affect you?
It affects zoraxy. Add what you run to find out whether that includes you.
No exploitation reported and no EPSS estimate yet.
Do this next
Free account, 1 product
Zoraxy is a general purpose HTTP reverse proxy and forwarding tool. Prior to version 3.3.2, an authenticated path traversal vulnerability in the configuration import endpoint allows an authenticated user to write arbitrary files outside the config directory, which can lead to RCE by creating a plugin. Version 3.3.2 patches the issue.
- CVSS
- 8.8 HIGH (v3.1, NVD)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
- Weakness (CWE)
- CWE-22
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- Not given
- NVD analysis
- Analyzed
- Record last updated
- Jun 17, 2026
- First seen by InfoSec Signals
- Oct 9, 2026
Affected products
zoraxy zoraxy zoraxy:zoraxy | before 3.3.2 | NVD |
References
- https://github.com/tobychui/zoraxy/commit/69ac755aeec5d15ba4c62099f7f1ed77a855b40bpatch
- https://github.com/tobychui/zoraxy/releases/tag/v3.3.2release-notes
- https://github.com/tobychui/zoraxy/security/advisories/GHSA-7pq3-326h-f8q9exploit, vendor-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.